Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


Ranbaxy Lab Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Apr 1, 2015 | Updated on Apr 1, 2015

Ranbaxy Lab: Get the latest Ranbaxy Lab Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at

A drug where Ranbaxy scores over Dr Reddy's

Jul 5, 2013

Equitymaster explains, which company is better of in the Isotretinoin drug in US.

Indian pharma: A walk through 'Para IVs'

Sep 21, 2012

Equitymaster explains the importance of Para IV filings for Indian pharma companies and which are the ones that are likely to benefit from possible outcomes.

Ranbaxy vs Dr. Reddy's: Which one is better? - III

Apr 8, 2011

This article is a comparison between Ranbaxy and Dr Reddy's balance sheet ratios and price performance over past 4 years.

Ranbaxy vs Dr. Reddy's: Which one is better? - II

Mar 26, 2011

This article is a comparison between Ranbaxy and Dr Reddy's revenue segmentation and other financial parameters.

Ranbaxy vs Dr. Reddy's: Which one is better?

Mar 23, 2011

This article is a comparison between Ranbaxy and Dr Reddy's profiles and their business segments.

Pharma: A second wave of generics opportunity

Jul 2, 2010

Equitymaster discusses the huge generics opportunity that beckons Indian pharma players in the US market in the next three years.

The next big thing for global Pharma

Oct 15, 2009

Today's article highlights the important role that branded generics are expected to play in the global pharmaceutical market and how Indian pharma will benefit from the same

Pharma: The year that was…

Apr 10, 2008

FY08 was a mixed year for Indian pharma companies. While the pricing pressure in the global generics market and the sharp appreciation of the rupee kept pharma companies on their toes, most of them barring the MNC pharma companies were able to log decent growth rates as compared to the previous two years both in revenues and profitability.

Pharma: Big guns, big dreams!

Feb 13, 2006

Companies from the pharma sector posted mixed results in the recently concluded December quarter. Barring Ranbaxy, the other large-cap pharma companies showed a relatively better performance. We have included four large-caps for the purpose of analysis of the sector's performance during the December quarter. These include Ranbaxy, Dr. Reddy's, Sun Pharma and Cipla. Glaxo has been excluded as the company has yet to declare its results.

Ranbaxy: Lipitor for the weak hearted?

Oct 14, 2005

Ranbaxy has been in the news for the past six months on account of its challenge to Pfizer's blockbuster drug 'Lipitor' in the UK as well as the US. In this article, we take a look why this patent challenge is regarded as the ‘mother of all patent challenges' in the global pharmaceutical industry and what has been the verdict so far.

Ranbaxy VS Dr. Reddy's: Clash of the titans!

Oct 5, 2005

Domestic pharma heavyweights, Ranbaxy and Dr.Reddy's have been the pioneers in establishing a global presence and moving ahead of competition in new drug discovery in the domestic pharma industry. While both the companies have similar business models (in respect of focus on generics and new drug discovery), we take a look at how these companies compare against each other on certain parameters.

Ranbaxy: What lies ahead...

Jun 3, 2005

Pharma major, Ranbaxy, has not had a great first quarter, much in line with its peers. VAT concerns and MRP based excise have led to sharp decline in domestic revenues. Its US operations too, continue to be under pressure. We take a look at its history and guage its prospects going forward.

Ranbaxy: Global strategy on course

Oct 15, 2004

Ranbaxy Laboratories, India’s largest domestic pharma company, has reported a good topline growth of 12% during the September quarter. However, there was weakness seen in the bottomline growth, which grew by 7.5%. For the first nine months of CY04, the company registered a growth of 13% on consolidated basis in sales, basically driven by strong growth in the European, CIS, African and Latin American market.

Generics: Long drawn journey!

Aug 18, 2004

US markets have been very lucrative for the Indian pharma companies and many companies such as Ranbaxy and Dr Reddy's capitalized on this opportunity. At the start, these companies entered the US as a supplier of bulk drugs, but with time they started looking at the more profitable generics business. In this article, we try to give you a perspective of what generics is all about and how do companies do generics business.

Ranbaxy Vs Watson

Aug 16, 2004

With almost US$ 55 bn worth of drugs going off patent in next 5 years, there is a huge opportunity for pharma companies in the generic space. Indian companies will compete with the world's very best for this pie. After looking at the US generics space, we found that Watson Pharma can provide a good comparison to Ranbaxy.

Cipla vs Peers

Aug 13, 2004

Cipla has seen a lot of activity over the past one month, and the stock has gained about 15% since July 2004. In the same period, the other two pharma giants, Dr Reddy's and Ranbaxy have gained only 3% and 6% respectively. So what has caught the investor's fancy with regard to Cipla? Let's find out.

Pharma: Global Vs local

Jun 10, 2004

There are two types of companies in the Indian pharma industry. While some are subsidiaries of global giants, others are home grown companies. Glaxo, Pfizer, Aventis and Novartis fall in the former category, while Ranbaxy, Cipla, Dr Reddy's, Wockhardt and Nicholas Piramal fall in the latter. Let's compare their business models and their performance.

Ranbaxy: Giant in the making…

Jun 9, 2004

Ranbaxy, undoubtedly the leader (in terms of size) in the Indian pharmaceutical industry is one of those companies, which over the last ten years has rewarded its shareholders well. Rs 100 invested in the stock in the July 1995 would have outperformed the benchmark Sensex by almost three and a half times, at a CAGR of about 18%.

Ranbaxy: Delivers a sweet pill

Oct 22, 2003

Ranbaxy has announced its 3QFY04 results. On a consolidated basis, the company has posted a topline growth of 14% and a bottomline growth of 25%. For 9mFY04, Ranbaxy has reported a 31% growth in net sales and a 35% rise in net profits. In this context let us make a detailed review of the company’s performance during the quarter.

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms